Market Overview

UPDATE: Citigroup Initiates Supernus Pharmaceuticals at Neutral; Fully Valued

Citigroup initiated coverage on Supernus Pharmaceuticals (NASDAQ: SUPN) with a Neutral/High Risk rating and a $14 price target.

Citigroup noted, "We recognize the potential opportunities for SUPN's extended release epilepsy drugs Oxtellar XR (SPN-804) and Trokendi XR (Extended release Topamax). However believe the company is currently fairly valued based on the risk associated with the company's commercial execution to recognize the potential value of these programs. Physician feedback has highlighted the importance of impact of early launch efforts/impact on long-term potential for an epilepsy product."

Supernus Pharmaceuticals closed at $11.39 on Monday.

Latest Ratings for SUPN

DateFirmActionFromTo
Apr 2014JefferiesInitiates Coverage onHold
Mar 2014Stifel NicolausMaintainsBuy
May 2013Piper JaffrayMaintainsOverweight

View More Analyst Ratings for SUPN
View the Latest Analyst Ratings

Posted-In: CitigroupAnalyst Color Initiation Intraday Update Analyst Ratings

 

Related Articles (SUPN)

Around the Web, We're Loving...

Get Benzinga's Newsletters